These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22323435)

  • 41. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.
    Chahlavi A; Todo T; Martuza RL; Rabkin SD
    Neoplasia; 1999 Jun; 1(2):162-9. PubMed ID: 10933051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line.
    Mriouah J; Boura C; Pinel S; Chretien AS; Fifre A; Merlin JL; Faivre B
    Int J Oncol; 2010 Dec; 37(6):1555-63. PubMed ID: 21042725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
    Kaliyaperumal K; Sharma AK; McDonald DG; Dhindsa JS; Yount C; Singh AK; Won JS; Singh I
    Redox Biol; 2015 Dec; 6():41-50. PubMed ID: 26177470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
    Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis.
    Jacinto JK; Co J; Mejia MB; Regala EE
    Br J Radiol; 2017 Nov; 90(1079):20170442. PubMed ID: 29053029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
    Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
    Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulsed Radiation Therapy With Concurrent Cisplatin Results in Superior Tumor Growth Delay in a Head and Neck Squamous Cell Carcinoma Murine Model.
    Meyer K; Krueger SA; Kane JL; Wilson TG; Hanna A; Dabjan M; Hege KM; Wilson GD; Grills I; Marples B
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):161-9. PubMed ID: 27511853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
    Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.
    Leeman-Neill RJ; Wheeler SE; Singh SV; Thomas SM; Seethala RR; Neill DB; Panahandeh MC; Hahm ER; Joyce SC; Sen M; Cai Q; Freilino ML; Li C; Johnson DE; Grandis JR
    Carcinogenesis; 2009 Nov; 30(11):1848-56. PubMed ID: 19762335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model.
    Dean NR; Knowles JA; Helman EE; Aldridge JC; Carroll WR; Magnuson JS; Clemons L; Ziober B; Rosenthal EL
    Anticancer Drugs; 2010 Oct; 21(9):861-7. PubMed ID: 20700044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and preclinical investigation of
    Shah SQ; Gul-E-Raana
    Mol Biol Rep; 2019 Apr; 46(2):1675-1682. PubMed ID: 30680596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance.
    Gerlach MM; Merz F; Wichmann G; Kubick C; Wittekind C; Lordick F; Dietz A; Bechmann I
    Br J Cancer; 2014 Jan; 110(2):479-88. PubMed ID: 24263061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Head and neck squamous cell carcinoma targeted chemosensitization.
    Figures MR; Wobb J; Araki K; Liu T; Xu L; Zhu H; O'Malley BW; Li D
    Otolaryngol Head Neck Surg; 2009 Aug; 141(2):177-83. PubMed ID: 19643248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
    Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
    Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
    Machiels JP; Kaminsky MC; Keller U; Brümmendorf TH; Goddemeier T; Forssmann U; Delord JP
    Invest New Drugs; 2013 Oct; 31(5):1207-16. PubMed ID: 23397499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
    Vermorken JB; Guigay J; Mesia R; Trigo JM; Keilholz U; Kerber A; Bethe U; Picard M; Brummendorf TH
    Br J Cancer; 2011 May; 104(11):1691-6. PubMed ID: 21540865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.